Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 13Triple Negative Breast Neoplasms 2Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Breast Carcinoma In Situ 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Thromboembolism 1Thrombocythemia, Essential 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Skin Diseases 1Sezary Syndrome 1Rectal Neoplasms 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplastic Cells, Circulating 1Neoplasms by Site 1Myeloproliferative Disorders 1Mycosis Fungoides 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1

Interventions

Anastrozole 8exemestane 7Trastuzumab 7Letrozole 7palbociclib 6Docetaxel 6abemaciclib 5Fulvestrant 5ribociclib 4pyrotinib 4entinostat 4Cyclophosphamide 4Tamoxifen 3Doxorubicin 3pertuzumab 2Sodium Chloride 2Paclitaxel 2Lapatinib 2Gonadotropin-Releasing Hormone 2Exercise 2Everolimus 2Epirubicin 2Drug Evaluation 2Capecitabine 2Botulinum Toxins, Type A 2Blood Specimen Collection 2Aromatase Inhibitors 2AZD9833 2tucatinib 1trastuzumab deruxtecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Diseases × Watchful Waiting × Breast × Clear all
NCT04016935 2022-05-17

EndoPredict® Extended Endocrine Trial (EXET)

Myriad Genetic Laboratories, Inc.

Terminated
855 enrolled
Breast

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Skin Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡